★ Analysts see FY2026 revenue reaching $198M — +19.0% growth in a single year.
What’s Driving the Stock
0123andMe's recent partnership with a leading pharmaceutical company for a new drug discovery program could unlock $50 million in revenue over the next two years.
02A surge in consumer interest for health-related genetic testing post-pandemic has led to a 25% increase in kit sales in Q1 2026.
03Potential regulatory approval for expanded health insights in genetic testing could significantly broaden the customer base.
04Growing consumer interest in personalized health solutions
05Increased integration of genetic data in healthcare decision-making
06Changes in consumer demand for genetic testing services
07Partnership announcements with pharmaceutical companies
"Management noted, 'We are seeing unprecedented interest in our services, and strategic partnerships are set to enhance our growth trajectory.'"
Moat: 23andMe's extensive genetic database and established brand recognition provide a strong competitive advantage in the personal genomics…
growth - Investors looking for exposure to innovative healthcare solutions and biotechnology advancements.
Interest rates affect the company's cost of capital and financing for R&D projects.
Watch on earnings: Consumer sentiment towards genetic testing services, Revenue growth rate from pharmaceutical partnerships, Customer acquisition and retention rates.
One Sentence Summary:
The bull case is simple: analysts see revenue climbing from $167M to $198M as 23andme's recent partnership with a leading pharmaceutical company for a new drug discovery program could unlock $50.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.
